Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1842 1
1848 2
1850 2
1851 1
1898 1
1901 1
1918 1
1919 8
1920 2
1922 3
1933 1
1936 2
1938 1
1946 2
1947 2
1948 2
1949 1
1950 1
1951 3
1952 3
1953 1
1954 3
1955 5
1957 3
1958 1
1959 1
1960 3
1961 1
1962 8
1963 12
1964 23
1965 21
1966 18
1967 21
1968 25
1969 34
1970 27
1971 39
1972 38
1973 28
1974 27
1975 38
1976 33
1977 30
1978 36
1979 34
1980 57
1981 35
1982 70
1983 57
1984 72
1985 64
1986 82
1987 91
1988 101
1989 94
1990 93
1991 93
1992 99
1993 117
1994 127
1995 127
1996 133
1997 155
1998 173
1999 178
2000 172
2001 149
2002 176
2003 188
2004 189
2005 225
2006 247
2007 272
2008 341
2009 351
2010 410
2011 406
2012 436
2013 527
2014 532
2015 622
2016 576
2017 613
2018 675
2019 669
2020 710
2021 821
2022 857
2023 797
2024 311

Text availability

Article attribute

Article type

Publication date

Search Results

12,492 results

Results by year

Filters applied: . Clear all
Page 1
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD Jr. Anderson LD Jr. Future Oncol. 2022 Jan;18(3):277-289. doi: 10.2217/fon-2021-1090. Epub 2021 Dec 2. Future Oncol. 2022. PMID: 34854741 Free article. Review.
As the first CAR T-cell product approved for myeloma, ide-cel is poised to become a practice-changing treatment option. ...Lay abstract Idecabtagene vicleucel (ide-cel) is a novel therapy using a patient's own T cells that have been genetically modified to force the …
As the first CAR T-cell product approved for myeloma, ide-cel is poised to become a practice-changing treatment option. ...Lay abstra …
Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging.
Corraliza-Gomez M, Bermejo T, Lilue J, Rodriguez-Iglesias N, Valero J, Cozar-Castellano I, Arranz E, Sanchez D, Ganfornina MD. Corraliza-Gomez M, et al. J Neuroinflammation. 2023 Oct 11;20(1):233. doi: 10.1186/s12974-023-02914-7. J Neuroinflammation. 2023. PMID: 37817156 Free PMC article.
These antecedents led us to address the impact of IDE absence in hippocampus and olfactory bulb. A specific induction of microgliosis was found in the hippocampus of IDE knockout (IDE-KO) mice, without any effects in neither hippocampal volume nor astrogliosi …
These antecedents led us to address the impact of IDE absence in hippocampus and olfactory bulb. A specific induction of microgliosis …
IDE Degrades Nociceptin/Orphanin FQ through an Insulin Regulated Mechanism.
Zingale GA, Bellia F, Ahmed IMM, Mielczarek P, Silberring J, Grasso G. Zingale GA, et al. Int J Mol Sci. 2019 Sep 10;20(18):4447. doi: 10.3390/ijms20184447. Int J Mol Sci. 2019. PMID: 31509943 Free PMC article.
However, the main hydrolytic fragments of OFQ/N produced by IDE exert inhibitory activity towards the IDE-mediated Ins degradation. Here, we present the results indicating that, besides Ins, IDE cleaves neuropeptides and their released fragments act as inhibi …
However, the main hydrolytic fragments of OFQ/N produced by IDE exert inhibitory activity towards the IDE-mediated Ins degrada …
ML345, A Small-Molecule Inhibitor of the Insulin-Degrading Enzyme (IDE).
Bannister TD, Wang H, Abdul-Hay SO, Masson A, Madoux F, Ferguson J, Mercer BA, Schurer S, Zuhl A, Cravatt BF, Leissring MA, Hodder P. Bannister TD, et al. 2012 Dec 17 [updated 2014 May 13]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. 2012 Dec 17 [updated 2014 May 13]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. PMID: 23833801 Free Books & Documents. Review.
Because IDE is the principal insulin-degrading protease in vivo, IDE inhibitors should enhance insulin signaling and thus have efficacy in relevant animal models of diabetes and also in therapy. Despite decades of study, a strong need yet exists for the identificati …
Because IDE is the principal insulin-degrading protease in vivo, IDE inhibitors should enhance insulin signaling and thus have …
Ide (Leuciscus idus) sperm short-term storage: Effects of different extenders and dilution ratios.
Cejko BI, Krejszeff S, Kowalski RK, Judycka S. Cejko BI, et al. Anim Reprod Sci. 2022 Dec;247:107155. doi: 10.1016/j.anireprosci.2022.107155. Epub 2022 Nov 19. Anim Reprod Sci. 2022. PMID: 36435052

A 4 (1:3) dilution ratio was compared to a 10 (1:9) dilution ratio for ide sperm storage using TLP supplemented with antibiotics and was tested for a 14-day period. ...The dilution ratio also had a significant impact (P < 0.0001) on the efficiency of ide sperm sh

…
A 4 (1:3) dilution ratio was compared to a 10 (1:9) dilution ratio for ide sperm storage using TLP supplemented with antibiotics and …
IDE: Image Dehazing and Exposure Using an Enhanced Atmospheric Scattering Model.
Ju M, Ding C, Ren W, Yang Y, Zhang D, Guo YJ. Ju M, et al. IEEE Trans Image Process. 2021;30:2180-2192. doi: 10.1109/TIP.2021.3050643. Epub 2021 Jan 26. IEEE Trans Image Process. 2021. PMID: 33476267
Experimental results show that IDE eliminates the dim effect and exhibits excellent dehazing performance. ...Comparison between the proposed IDE and other state-of-the-art techniques reveals the superiority of IDE in terms of both dehazing quality and efficie …
Experimental results show that IDE eliminates the dim effect and exhibits excellent dehazing performance. ...Comparison between the p …
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Papatheodoridis GV, et al. J Hepatol. 2010 Aug;53(2):348-56. doi: 10.1016/j.jhep.2010.02.035. Epub 2010 Apr 27. J Hepatol. 2010. PMID: 20483498 Free article. Review.
BACKGROUND & AIMS: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from stud …
BACKGROUND & AIMS: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucl …
Exchange Broadening Underlies the Enhancement of IDE-Dependent Degradation of Insulin by Anionic Membranes.
Zheng Q, Lee B, Kebede MT, Ivancic VA, Kemeh MM, Brito HL, Spratt DE, Lazo ND. Zheng Q, et al. ACS Omega. 2022 Jul 7;7(28):24757-24765. doi: 10.1021/acsomega.2c02747. eCollection 2022 Jul 19. ACS Omega. 2022. PMID: 35874268 Free PMC article.
However, IDE also degrades monomers of amyloidogenic peptides associated with disease, complicating the development of IDE inhibitors. ...Using NMR spectroscopy, we discovered that exchange broadening underlies the enhancement of IDE's activity. These finding …
However, IDE also degrades monomers of amyloidogenic peptides associated with disease, complicating the development of IDE inh …
Insulin-degrading enzyme.
Authier F, Posner BI, Bergeron JJ. Authier F, et al. Clin Invest Med. 1996 Jun;19(3):149-60. Clin Invest Med. 1996. PMID: 8724818 Review.
IDE is the first cloned and characterized proteinase to be localized to peroxisomes. Moreover, IDE appears to be a member of a newly identified superfamily of metalloendopeptidases that has an HXXEH active-site motif. ...
IDE is the first cloned and characterized proteinase to be localized to peroxisomes. Moreover, IDE appears to be a member of a …
12,492 results
You have reached the last available page of results. Please see the User Guide for more information.